Current Innovations In Contained Manufacturing

By Michael Avraam, Head of Solutions Engineering, ChargePoint Technology

The highly potent active pharmaceutical ingredient (HPAPI) market is experiencing huge growth; valued at around US$17billion in 2018, it is anticipated to grow to $26 billion by 2023.

Something driving this growth is the additional knowledge being obtained for existing compounds that were previously not considered to be HPAPIs. As new toxicity data are generated, some of these compounds are being reclassified as HPAPIs. This is coupled with rising cancer rates, which are creating an increasing demand for more effective, better targeted medications using potent compounds.

Establishing an effective containment infrastructure is key to any production involving HPAPIs. Employee safety is paramount; however, regulatory compliance is also critical. To that end, managing the manufacture of new and reclassified HPAPIs is placing increasing pressure on existing manufacturing facilities.

Continue reading to learn more about procedures and new technologies that can assist you in meeting your high potency handling requirements and ensure the safety of your employees.